Omixon announce today a new partnership with Commugene in South Korea. Through our cooperation, from one of the fastest growing markets in the world, researchers in the biotechnology industry will have easier access to Omixon’s high-performance, high-throughput and high-resolution multi-sample kit and software only products for HLA genotyping analysis by Next Generation Sequencing for use on the Illumina Sequencers.

“We are thrilled to working alongside Commugene in South Korea. Their commitment to excellence, knowledge of the local HLA typing market and bringing early NGS for HLA opportunities to our attention were all key differentiators in selecting them to represent Omixon” commented Peter Meintjes, CCO, Omixon.

Omixon has trained over 80 HLA labs worldwide, 15 labs are in clinical routine and 10 labs are already accredited with the ASHI or EFI standards.

“We believe that the Holotype HLA NGS kit and HLA Explore our primary research use software product for HLA Genotyping by NGS will be very attractive to the scientific community in South Korea” commented Nora Nagy, Market Development Manager, Omixon.

We look forward to a strong relationship!

For further details on how to become an appointed Omixon distributor for your region, please contact us at sales@omixon.com